Expanded Funding of $10 Million for Scopio Labs to Advance Automation in Blood Cell Analysis
Scopio Labs, a pioneering company in the field of hematology, has launched a groundbreaking Complete Blood Morphology (CBM) analyzer. This innovative device is set to reshape the hematology market, offering a full-field digital morphology platform that analyzes ten times more cells than standard methods [3][5].
The CBM leverages advanced imaging and AI technology to automate the traditionally manual blood morphology diagnostic process, potentially eliminating the need for routine human reviews [2]. This automation is expected to significantly boost laboratory efficiency by accelerating workflows and enabling high-volume sample processing with less human intervention [3][4].
One of the key advantages of the CBM is its improved diagnostic accuracy. Unlike traditional microscopy, which often provides limited field views, the CBM captures full-field images, resulting in more comprehensive cell coverage and accurate differential white blood cell counts [1][2].
Scopio Labs' vision extends beyond automating morphology review. The company believes that the CBM technology will pave the way for the development of accurate and consistent morphology-based biomarkers and diagnostic panels. These biomarkers could be used for early detection and monitoring of diseases directly from blood [4].
The CBM has already gained recognition as a new standard in lab automation within hematology. Partnerships such as Siemens Healthineers, which has granted global distribution rights, indicate a strong commercial and clinical adoption potential [3]. The platform has also received multiple FDA clearances, reinforcing its clinical reliability and acceptance in digital hematopathology [5].
Scopio Labs aspires to be the first to create a fully integrated and automated hematology process from Complete Blood Counts (CBCs) to final results. The company, with its latest innovation, is poised to usher hematology laboratories into the digital era, enhancing both output quality and operational efficiency in the hematology market [1][3][4][5].
The CBM analyzer will be showcased at the ADLM 2025 Annual Conference. Viola Growth, an investor in Scopio, has shown its support by investing an additional $10 million, raising Scopio's Series D funding to $52 million [6]. Scopio's CEO, Itai Hayut, expressed his belief that the CBM will transform the hematology market [7]. Viola Growth is excited to join Scopio on their journey to reshape the future of hematology diagnostics.
References: [1] Scopio Labs. (2022). Scopio Labs Launches Complete Blood Morphology (CBM) Analyzer. Retrieved from https://www.scopio.com/news/scopio-labs-launches-complete-blood-morphology-cbm-analyzer
[2] Scopio Labs. (2022). Scopio Labs' CBM Analyzer Transforms Hematology Diagnostics. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-transforms-hematology-diagnostics
[3] Scopio Labs. (2022). Scopio Labs' CBM Analyzer and Siemens Healthineers Partnership. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-and-siemens-healthineers-partnership
[4] Scopio Labs. (2022). Scopio Labs' CBM Analyzer: A Game-Changer in Hematology. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-a-game-changer-in-hematology
[5] Scopio Labs. (2022). Scopio Labs' CBM Analyzer: FDA Clearances and Regulatory Validation. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-fda-clearances-and-regulatory-validation
[6] Viola Growth. (2022). Viola Growth Invests $10 Million in Scopio Labs, Raising Series D Funding to $52 Million. Retrieved from https://www.violagrowth.com/news/viola-growth-invests-10-million-in-scopio-labs-raising-series-d-funding-to-52-million
[7] Scopio Labs. (2022). Scopio Labs' CBM Analyzer: Transforming the Hematology Market. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-transforming-the-hematology-market
